Released Mar 17, 2025, before the open
10-K filed Mar 17, 2025, 76 days after period end · 0001558370-25-003039
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$18.22M$18.22M derived+73.7% vs Q4 2023+1.4% vs Q3 2024
Net Income$6.49M$6.49M derivedN/M vs Q4 2023+100.7% vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$7,209,000N/M
Operating Cash Flowderived$3,991,000+11.0%
Free Cash Flowderived$3,566,000+6.6%
Margins · derived
Operating margin39.6%+93.1 pt vs Q4 2023
Net margin35.6%+93.3 pt vs Q4 2023
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $18.22M | $10.49M | $8.62M | $8.55M |
| Net Income | $6.49M | -$6.04M | -$3.74M | -$6.67M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR